Strona główna

Str. 34 Sławomir Dutkiewicz


Pobieranie 14.53 Kb.
Data19.06.2016
Rozmiar14.53 Kb.

Str. 34

Sławomir Dutkiewicz


Zmiana standardów diagnostyczno - leczniczych w postępowaniu z chorymi na łagodny rozrost gruczołu krokowego.

Piśmiennictwo

  1. Mc Neal J E. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin N Amer 1990;17: 477-486.

  2. Dutkiewicz S. Zdrowie mężczyzn Układ moczowy i płciowy. Amedic, Warszawa 2002.

  3. Barry M, Cockett AT K, Holtgrewe H L, et al. Relatinoship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostate hyperplasia. J Urol 1993; 150: 351-358.

  4. Speakmen M. LUTS, BPH, BPE, BPO – stop the confusion! Eur Urol Today Conngress News2009;Thursday 19: 2.

  5. Radziszewski P, Kozłowski R, Dobroński P. Nietrzymanie moczu u chorych na łagodny rozrost stercza. Przegl Urol 2007; 8,3,(43): 63-68.

  6. Dutkiewicz S. Badania nad określeniem czynników warunkujących wybór leczenia farmakologicznego lub chirurgicznego u chorych na łagodny rozrost stercza. Legraf, Warszawa 1996.

  7. Gades N M, Jacobson D J, Girman C J, et al . Prevalence of conditions potentially associated with lower urinary tract symptoms in men. B J U Inter 2005; 95: 549-553.

  8. Kawakami J, Nicke I J C. Acute urinary retention and surgery for benign prostatic hyperplasia the patients perspective. Can J Urol 1999; 6: 819-822.

  9. .KaplanS A. Benign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How they can be useful to primary care.V.1,No.1, , Weil Medical College of New York University 2006.

  10. Emberton M, Fitzpatrick J M, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: systemic review of the placebo arms clinical trials. B J U Inter 2008; 102(8): 981-986.

  11. Choong S, Emberton M. Acute urinary retention. B J U Int. 2000; 85: 186-201.

  12. Borówka A. Leczenie – uwagi ogólne, kryteria wyboru metody leczenia. W: Borkowski A, Borówka A. (red): Choroby gruczołu krokowego, PZWL, Warszawa 1997 (ss.128-134).

  13. EUA Guidelines Pocket Edition 3, Benign Prostatic Hyperplasie, Board EUA, Arnhem – the Netherlands, 2005, 4-11.

  14. Marberger M. BPH therapy. Sympozjum 16.03.2005 r. podczas XX Zjazdu EAU w Stambule, Turcja.

  15. Madersbracher S, Alivizatos G, Nordling J,et al. Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction, Przegl Urol 2006; 7: 50-55.

  16. Kaplan S A. Minimally invasive therapies for benign prostatic hyperplasia in the new millenium: long-term data. J Urol 2002; 168: 1661-1665.

  17. Mc Connelli D, Roehrborn O M, Bautista G L, et al for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-therm effect of doxazosin, finesteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New Engl J of Med 2003; 349: 2387-2398.

  18. Kirby R S, Lepor H, Roehrborn C G, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-126.

  19. Barkin J, Guimaraes M, Jacobi G, et al, (SMART Investigator Group). Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44, 4: 461-466.

  20. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha-1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64:1081-1088.

  21. Kaplan S A. Identification of the patient with enlarged prostate: diagnosis and guidelines for management. www. Osteopath Med Prim Care 2007;1:11.

  22. Kirby R S, Pool J L. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia : past, present and future,B J Urol 1997; 80: 521-532.

  23. Lepor H. Prostate selectivity of alpha-blockers: from receptor biology to clinical medicine. Eur Urol 1996; 29, Suppl.1,12.

  24. Januszewicz A, Prejbisz A. Leczenie nadciśnienia tętniczego u chorych z łagodnym rozrostem gruczołu krokowego. Terapia 2008; 7-8 (211-212): 3-7.

  25. Roehrborn C G, Boyle P, Nickel J C, et al . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-441.

  26. Bartsch G., Rittmaster R S, Klocker H. Dihydrotestosterone and the concept of 5-alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-380.

  27. Andriole G L, Kirby R. Safety and tolerability of the dual 5-alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82-88.

  28. Crea G, Sanfilippo G, Anastasi G, et al. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int 2005; 74: 51-53.

  29. Rosner: Proscar and Propecia – a therapeutic prospective. J Clin Endocrinology and Metabolism 2004; 89 (7): 3096-3098.

  30. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res 2008; www.CAPR -08-0085.

  31. Teillac P. Sympozjum pt. “Era po badaniach MTOPS i PCPT czy istnieje potrzeba zmian w naszej praktyce klinicznej” – XX Zjazd European Association of Urology, Stambuł 16. 03. 2005 r.

  32. Marberger M. The MTOPS study: new findings, new insights, and clinical implications for the management of BPH. Eur Urol Suppl 2006; 5: 628-633.

  33. Mochtar C A, Kimeney L A, Van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695-697.

  34. Baldwin K C, Ginsberg PC, Harkaway R C. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int 2001; 66: 84-88.

  35. Roehrborn C, Heaton J. Medical management for BPH: The role of combination therapy. Eur Urol 2003; Supl 5, 12: 716-721.

  36. Teillac P., Abrahamsson P. A.: The role of finasteride in the management of BPH and in the prevention ofprostate cancer, Eur.Urol.Suppl. 2006, 5, 627.

37.Dutkiewicz S. A practical algorithm management of patients with benign prostatic hyperplasia. Journal of Pre-Clinical and Clinical Research 2009;v.2,no.2:1-10.

  1. Malek R S, Guest Editor. GreenLight HPS laser therapy for BPH: clinical outcomes and surgical recommendations from the International GreenLight User Group (IGLU). Eur Urol 2008; suppl.7,4: 361-392.

  2. Kwinta a, Walkiewicz R. Leczenie chorych na łagodny rozrost stercza (BPH) fotoselektywną waporyzacją stercza PVP laserem GreenLight KTP – doświadczenia własne. Urol Pol 2008; 61,4: 292-300.

  3. Ostri P. TURis plasma vaporization a clinical experience. Interview during 24-th Annual EAU Congress in Stockholm, and :TURis plasma vaporization – a future procedure in prostate management.EUT Congress News2009,tharsday 19 March,p.5.

.

.


©snauka.pl 2016
wyślij wiadomość